Vaccine Research Programs
The organizational structure of the CVC includes three scientific discovery programs and five programs of immune therapeutic application. Researchers are working collaboratively with clinical investigators in specific disease programs to carry out clinical trials in patients with different types of cancer.
Three key programs involving immunology are central to the research effort at the CVC.
- Tumor Antigens: focused research effort to select the most appropriate cancer vaccine targets for individual cancers for evaluation in clinical trials
- Immune Response: systematic analysis of immunogenicity of T cell and B cell peptide epitopes, and cytokine immune assessments
- Immune Regulation: examination of methods for sustaining tumor immunity in patients undergoing active immunization
Immune Therapeutics Development
New strategies and distinct vaccine technologies are being utilized at the CVC as part of our ongoing process to create effective new cancer therapies.
- Antigen Vaccines: integration of research and clinical efforts using well-defined tumor antigens in carefully designed clinical trials
- Cellular Vaccines: whole tumor cells used in allogeneic and autologous vaccine strategies for durable, broadly effective anti-tumor response
- Immune Cells: direct administration of immune effector cells as adoptive cell therapy
- Antibody Therapies: exploration of antibodies directed at surface components of tumors and as blockade of negative immunoregulatory mechanisms that impede immunotherapy
- Nanotechnology: application of nanoscale devices for development of vaccines, including directed delivery of immune stimulants and antigens